Medical Policy

W-2264-001

Policy Id

HHO-WV-RP-2264

Topic

Lab Panel Testing

Section

Laboratory

Effective Date

Nov 01, 2025

Issued Date

Oct 01, 2025

Last Revision Date

07/2025

DISCLAIMER

Highmark Health Options medical policy is intended to serve only as a general reference resource regarding coverage for the services described. This policy does not constitute medical advice and is not intended to govern or otherwise influence medical decisions.

POLICY STATEMENT

Highmark Health Options may provide coverage under medical surgical benefits of the Company’s Medicaid products for medically necessary. Refer to the Noncovered Services policy for more information.

This policy is designed to address medical necessity guidelines that are appropriate for the majority of individuals with a particular disease, illness or condition. Each person’s unique clinical circumstances warrant individual consideration, based upon review of applicable medical records.

The qualifications of the policy will meet the standards of the National Committee for Quality Assurance (NCQA) and the West Virginia Department of Health and Human Resources (DHHR) and all applicable state and federal regulations.

 

 

 

86592

Syphilis test, non-treponemal antibody; qualitative (eg, VDRL, RPR, ART)

86593

Syphilis test, non-treponemal antibody; quantitative

87285

Infectious agent antigen detection by immunofluorescent technique; Treponema pallidum

87490

Infectious agent detection by nucleic acid (DNA or RNA); Chlamydia trachomatis, direct probe technique

87491

Infectious agent detection by nucleic acid (DNA or RNA); chlamydia trachomatis, amplified probe technique

87492

Infectious agent detection by nucleic acid (DNA or RNA); Chlamydia trachomatis, quantification

87534

Infectious agent detection by nucleic acid (DNA or RNA); HIV-1, direct probe technique

87535

Infectious agent detection by nucleic acid (DNA or RNA); HIV-1, amplified probe technique, includes reverse transcription when performed

87536

Infectious agent detection by nucleic acid (DNA or RNA); HIV-1, quantification, includes reverse transcription when performed

87537

Infectious agent detection by nucleic acid (DNA or RNA); HIV-2, direct probe technique

87538

Infectious agent detection by nucleic acid (DNA or RNA); HIV-2, amplified probe technique, includes reverse transcription when performed

87539

Infectious agent detection by nucleic acid (DNA or RNA); HIV-2, quantification, includes reverse transcription when performed

87590

Infectious agent detection by nucleic acid (DNA or RNA); Neisseria gonorrhoeae, direct probe technique

87591

Infectious agent detection by nucleic acid (DNA or RNA); neisseria gonorrhoeae, amplified  probe technique

87592

Infectious agent detection by nucleic acid (DNA or RNA); Neisseria gonorrhoeae, quantification

87661

Infectious agent detection by nucleic acid (DNA or RNA); trichomonas vaginalis, amplified probe technique

87808

Infectious agent antigen detection by immunoassay with direct optical (ie, visual) observation; Trichomonas vaginalis

 

 

Appliciable comprehensive code

 

 

87801

Infectious agent detection by nucleic acid (DNA or RNA), multiple organisms; amplified probe(s) technique

References

American Medical Association, Current Procedural Terminology (CPT®) and associated publications and services.

 

Centers for Medicare and Medicaid Services, CMS Manual System and other CMS publications and services.

https://www.cms.gov/Regulations-and-Guidance/Guidance/Transmittals/downloads/R2997CP.pdf

 

Centers for Medicare and Medicaid Services, National Correct Coding Initiative (NCCI) publications.

 

WV Policy Manual 

Images

Contact Us

For questions related to this policy, contact the Highmark Government Market Policy Team at GovernmentPolicy@Highmark.com